Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma

Figure 1 Kaplan-Meier disease-free survival curves for hepatocellular carcinoma patients who carried different multidrug resistance related protein-1 -1666 genotypes. A: Comparison between three genotypes; B: GG genotype compared with the other two genotypes. Log-rank P values are indicated. Tick marks represent censored data. DFS: Disease-free survival.

Figure 2 Kaplan-Meier curves for disease-free survival (A and B) and overall survival (C and D) for male patients with hepatocellular carcinoma and different multidrug resistance related protein-1 -1666 genotypes. A: Comparison of disease-free survival (DFS) between three genotypes; B: AA and AG grouped together and compared to GG genotype; C: Comparison of overall survival (OS) between three genotypes; D: OS of AA and AG genotypes compared with GG genotype. Log-rank P values are indicated. Tick marks represent censored data.

Figure 3 Electrophoretic mobility shift assay of the multidrug resistance related protein-1 promoter region that contained the G-1666A site. A: Analysis was performed in the presence (+) or absence (-) of Hep3B nuclear extract. Each binding reaction contained γ-³²P-labeled -1666G (lanes 2-8) or -1666A (lanes 10-14) probes. A 10-, 50-, or 100-fold (as indicated) excess of unlabeled (cold) -1666A or G oligonucleotides (lanes 6-8, 11, and 12 or 3-5, 13, and 14) were included in the binding reactions as specific competitors. Labeled oligonucleotides incubated without the nuclear extracts were included as negative controls (lanes 1 and 9); B: In the present of Hep3B nuclear extract, 10- or 50-fold more excess of unlabeled -1666G oligonucleotides (lanes 3 and 4) or -1666A oligonucleotides (lanes 5 and 6) or non-specific oligonucleotides (lanes 7 and 8) were used as competitors. Lane 1 was the negative control. Lane 2 indicated the labeled -1666G oligonucleotides incubated with the nuclear extracts only. The asterisks indicated the DNA-protein complex.